Related Experiment Videos
Targeted therapy for multiple myeloma
1Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Abstract:
Multiple myeloma (MM) remains incurable with conventional treatment approaches, and novel biologically based therapies are therefore urgently needed. Targeted therapies are either under development or already undergoing clinical evaluation predicated upon: identifying genetic abnormalities in myeloma cells to enhance chemoradiosensitivity; interrupting growth or triggering apoptotic signaling cascades in tumor cells; treating both the tumor cell and its microenvironment; enhancing allogeneic and autologous antimyeloma immunity; and characterizing new myeloma antigens for serotherapy. These therapies, alone or in combination with conventional treatments, offer great promise to improve the outcome for patients with MM.
Insights
Novel targeted therapies are crucial for treating incurable multiple myeloma (MM). Research focuses on genetic targeting, apoptosis induction, microenvironment modulation, immune enhancement, and new antigen discovery for improved patient outcomes.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Background:
- Multiple myeloma (MM) is an incurable hematologic malignancy.
- Conventional treatments have limitations, necessitating novel therapeutic strategies.
- There is an urgent need for biologically based therapies for MM.
Purpose of the Study:
- To review and highlight novel, biologically based therapies for multiple myeloma.
- To discuss targeted treatment approaches currently in development or clinical evaluation for MM.
- To emphasize the potential of these novel therapies to improve patient outcomes.
Main Methods:
- Identification of genetic abnormalities in myeloma cells to enhance sensitivity to chemotherapy and radiation.
- Interruption of tumor cell growth and induction of apoptosis through targeted signaling pathways.
- Therapeutic strategies targeting both myeloma cells and their surrounding microenvironment.
- Enhancement of both allogeneic and autologous immune responses against myeloma.
- Characterization of novel myeloma antigens for the development of serotherapies.
Main Results:
- Multiple targeted therapy strategies are under active investigation for multiple myeloma.
- These approaches aim to overcome limitations of conventional treatments.
- Combinations of targeted therapies with conventional treatments show promise.
Conclusions:
- Novel targeted therapies offer significant promise for improving outcomes in multiple myeloma.
- These therapies address key biological aspects of myeloma, including genetic vulnerabilities and immune evasion.
- Further development and clinical evaluation are essential to realize the full potential of these treatments for MM patients.